A phase II, multicentre study to evaluate the long-term safety and efficacy of MT-1303 in subjects with relapsing-remitting multiple sclerosis who have completed the MT-1303-E04 study
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2019
At a glance
- Drugs Amiselimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms Momentum
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 08 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 21 Aug 2014 Last checked against United Kingdom Clinical Research Network record.